The Company is creating the first ever cable-free synthesized 12-lead ECG capable of capturing the heart’s electrical signals from three distinct directions. This platform technology is designed ...

including heart attack. Kardia 12L performed comparably to the standard 12-lead ECG in detecting major morphology-related abnormalities. "AliveCor's Kardia 12L ECG System was born from our vision ...

HeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...

The purpose of this study was to evaluate whether the 12-lead ECG could be substituted by ECG sets with a limited number of leads. Materials and methods: The performance of three ECG systems (ie ...

Cardiovascular disease affects nearly half of the adults in the United States, posing a significant public health challenge.

HeartBeam (NASDAQ: BEAT) , a medical technology company advancing cardiac care, has submitted a 510 (k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram ( ...

Medical technology company HeartBeam has secured two new patents from the US Patent and Trademark Office on its core vector electrocardiography (VECG) technology. HeartBeam’s VECG technology ...

It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen’C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio’B ...

The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five ...